Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Free State Receives R7 Million Grant from the Mellon Foundation for Arts Innovation
2015-11-30


Man in the Green Blanket, Lesiba Mabitsela.
Photo: Karla Benade

Bloemfontein will experience a flood of new, experimental art over the next four years as a result of R7 million that has been received to develop experimental art projects in central South Africa. The Andrew W. Mellon Foundation recently awarded the grant to the University of the Free State (UFS) for the Programme for Innovation in Artform Development (PIAD). Initiated jointly by the UFS and the Vrystaat Arts Festival in 2014, PIAD was established as a programme to promote the exploration of the arts to advance interdisciplinary research and to impact on human development.

The Andrew W. Mellon Foundation is a New York-based, non-profit organisation which endeavours to strengthen, promote, and, where necessary, defend the contributions of the humanities and the arts to human flourishing, and to the well-being of diverse and democratic societies.

“The Innovation in Artform Development initiative will provide an important contribution to the ways in which the university hopes to broaden and deepen research and dialogue about the humanities in South African society. Using the arts as a vehicle to engage communities around issues of social significance, makes for an exciting endeavour, and we are happy to have Mellon’s financial and partnership investment in this initiative,” said Prof Jonathan Jansen, Vice-Chancellor of the UFS.

“This substantial support from the Foundation will play a pivotal role in facilitating collaborations with national and international artists to explore new, innovative modes of artistic practice and creative production in South Africa,” said Angela de Jesus, UFS Art Curator and Co-Director of PIAD.

“A series of First Nations projects, arts/science research and artist residencies, arts laboratories for creative practitioners, the production of exciting new work for Bloemfontein, and critical debates/forums is expected over the next few years,” she added.

PIAD focuses on supporting cross-cultural, experimental art programmes that can assist South African society creatively. For this process, PIAD is engaging the skills and expertise of South Africa artists in collaboration with several international partners, who are recognised as global leaders in this field, to develop a mutually- beneficial programme of engagement.  

Innovation, technology, and new forms of art will be explored and international collaborations that have the potential to attract benefits for the creative industries in Bloemfontein and beyond will be introduced.

“The artistic landscape of the Free State - in fact the whole South Africa - will be forever changed because of this extraordinarily generous grant. Rarely does a regional community get a chance to lead innovation on a national scale, and also impact on experimental art internationally. We are in for an incredible artistic journey,” said Dr Ricardo Peach, Director of the Vrystaat Arts Festival and Co-Director of PIAD.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept